Investing in Johnson & Johnson.
Johnson & Johnson has been a part of people's lives for 128 years and a valuable part of their investments for approximately 70 years. Founded in 1886, we listed our shares on the New York Stock Exchange for public investors in 1944.
During our history, we have built the most comprehensive base of health care businesses in the world, generating approximately 70 percent of our revenues from No. 1 or No. 2 global leadership positions in our respective markets.
Our consistent performance has enabled us to deliver an exceptional track record of growth that few, if any, companies can claim: 30 consecutive years of adjusted earnings increases; and 51 consecutive years of dividend increases. Over the last 10 years, Johnson & Johnson stock generated a 8.9 percent total return for investors compared to a 7.4 percent total return for the S&P 500.(1)
April 15, 2014
Johnson & Johnson Reports 2014 First-Quarter Results:
April 12, 2014
Final Data from the Phase 2 COSMOS Study of Janssen's Once-Daily Simeprevir in Combination with Sofosbuvir Presented at The International Liver Congress™ 2014 of the European Association for the Study of the Liver (EASL)
April 8, 2014
Supplemental New Drug Application for IMBRUVICATM (ibrutinib) Submitted to the U.S. FDA
April 24, 2014 at 10:00 AM ET
Johnson & Johnson 2014 Annual Meeting of Shareholders
April 15, 2014 at 8:30 AM ET
Johnson & Johnson First Quarter 2014 Earnings Call and Webcast
Financial Quick Links
1. Data source - Bloomberg